Serpin F1/PEDF 組換え体(リコンビナント)タンパク質 | Recombinant Human Serpin F1/PEDF

掲載日情報:2018/02/08 現在Webページ番号:216302

R&D Systems社製の高品質なSerpin F1/PEDFの組換え体タンパク質(Recombinant Human Serpin F1/PEDF)です。
本製品は研究用です。研究用以外には使用できません。

[在庫・価格 :2024年05月10日 20時15分現在]

※ 表示されている納期は弊社に在庫が無く、取り寄せた場合の納期目安となります。
詳細 商品名
  • 商品コード
  • メーカー
  • 包装
  • 価格
  • 在庫
  • 法規制等
納期 文献数
Recombinant Human Serpin F1/PEDF, CF
10日程度 ※ 表示されている納期は弊社に在庫がなく、取り寄せた場合の目安納期となります。 1
説明文
純度:>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.,由来動物:Human,M.W.:45 kDa,Genbank:5176,エンドトキシンレベル:<1.0 EU per 1 µg of the protein by the LAL method.,産生:NS0
別名:Cell proliferation-inducing gene 35 protein
Genbank No: 5176
Protein Accession No: AAK92491
法規制等
保存条件 -20℃ 法規備考
掲載カタログ

製品記事 Anti-Human IRF4 Polyclonal Antibody
関連記事

[在庫・価格 :2024年05月10日 20時15分現在]

※ 表示されている納期は弊社に在庫が無く、取り寄せた場合の納期目安となります。

Recombinant Human Serpin F1/PEDF, CF

文献数: 1

説明文 純度:>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.,由来動物:Human,M.W.:45 kDa,Genbank:5176,エンドトキシンレベル:<1.0 EU per 1 µg of the protein by the LAL method.,産生:NS0
別名:Cell proliferation-inducing gene 35 protein
Genbank No: 5176
Protein Accession No: AAK92491
法規制等
保存条件 -20℃ 法規備考
掲載カタログ

製品記事 Anti-Human IRF4 Polyclonal Antibody
関連記事

バルク注文に関して

バルク包装品も承ります。お気軽にお問合せ下さい。

目次に戻る

CF(Carrier-Free)とは?

R&D Systems社組換え体タンパク質製品では通常ウシ血清アルブミン(BSA)をキャリアタンパク質として加えています。キャリアタンパク質を加えることで組換え体タンパク質の安定性が高まり、使用期限が長くなります。また、より濃度の低い溶液での保管も可能となります。CF製品はBSAが含まれない製品となります。一般的に細胞培養や、ELISAのスタンダードにはBSA含有製品を推奨しています。CF製品はBSAが影響してしまうアプリケーションに推奨されます。

目次に戻る

Product Details

Source
Mouse myeloma cell line, NS0-derivedMet1-Pro418, with a C-terminal 6-His tag
Accession #
AAK92491
Purity
>95%, by SDS-PAGE under reducing conditions and visualized by silver stain
Predicted Molecular Mass
45 kDa
SDS-PAGE
45-53 kDa, reducing conditions
Activity
Measured by its ability to enhance the adhesion of Saos‑2 human osteosarcoma cells to bovine Collagen I coated plate. Eth, E.K. et al. (2007) Cancer Gene Therapy. 14:616. The ED50 for this effect is 0.15-0.75 μg/mL.

目次に戻る

Related Product & Information

Entrez Gene IDs
5176 (Human); 20317 (Mouse); 287526 (Rat)
Background
Serpin F1/PEDF
Serpin F1 (SERine Proteinase Inhibitor‑clade F1; also PEDF/Pigment Epithelium‑Derived Factor, EPC‑1 and PIG35) is a monomeric, 52‑55 kDa secreted phosphoglycoprotein that belongs to the clade F subfamily, serpin superfamily of proteinase inhibitors (1‑4).  Serpins in general form two groups: one that demonstrates protease inhibition, and another (containing Serpin F1) whose members show no protease inhibition, but which act as chaperones and circulating transporters (2)   Serpin F1 is synthesized as a 418 amino acid (aa) precursor that contains a 19 aa signal sequence plus a 399 aa mature region that shows a pyroglutamate at Gln20 (5, 6, 7).  Like other serpins, it contains three beta ‑sheets, 8‑10 alpha ‑helices, and a C‑terminal RCL (reactive center loop).  Unlike other serpins with Ser protease inhibiting activity, the RCL of Serpin F1 does not undergo a conformational change upon target protease cleavage, a prerequisite for anti‑protease activity.  Such cleavage does, however, generate a 46 kDa fragment that possesses nonprotease‑associated (i.e.‑neurotrophic) bioactivity (8).  Phosphorylation occurs both intracellularly and extracellularly. Intracellularly, PKA phosphorylates Ser227, promoting anti‑angiogenic activity.  Extracellularly, CK2 phosphorylates Ser24 and Ser114, promoting neurotrophic activity (9).  Multiple sites have been identified and associated with distinct biological activities.  Amino acids 63‑70 constitute a functional NLS, and a 36 kDa Serpin F1 isoform has been reported in the nucleus (10).  In addition, lipase activity (perhaps a consequence of receptor binding) has been mapped to aa 78‑141, anti‑angiogenic activity to aa 20‑70 plus Ser114 and Ser227, neurotrophic activity to aa 32‑141, and heparin binding to aa 121‑149 (4).  Mature human Serpin F1 shares 86% aa sequence identity with mouse Serpin F1. Serpin F1 is known to be synthesized by multiple cell types, including retinal pigment epithelium (RPE), fibroblasts, mammary epithelium, preadipocytes and adipocytes, hepatocytes, osteoblasts and osteoclasts (1, 2, 11‑15).  This diversity of cell types reflects its many activities, among which are neuroprotection, lipolysis, antiangiogenesis, and anticarcinogenesis (2‑4).  Much work has been done with RPE, a cell type that is known to both provide neuroprotection and block angiogenesis.  On the neuroprotection side, Serpin F1 binding to an 83 kDa, 4‑transmembrane PEDF receptor (also known as PNPLP2 and TTS‑2.2) results in the activation of receptor‑associated PLA2 activity.  This activity is directed towards RPE membrane triglycerides that contain a dietary omega ‑3 fatty acid called DHA.  Once released via lipase activity, DHA is converted into NDP1, a neuroprotective lipid that acts on the surrounding neural complex (2, 16‑18).  RPE‑derived Serpin F1 also minimizes retinal vascularization.  This apparently occurs through a variety of mechanisms.  First, Serpin F1 binds to PEDFR on endothelial cells (EC), generating PPAR gamma ligands via EC CYP450.  These ligands activate PPAR gamma induces p53 and subsequent EC apoptosis (19, 20).  Second, Serpin F1 apparently binds the 67 kDa laminin receptor (LR) on EC.  This activates caspase‑3 with the initiation of an apoptotic program (21).  Finally, Serpin F1 interfers with VEGF signaling.  This appears to happen through at least two mechanisms.  First, there is a direct competitive binding of Serpin F1 to the EC VEGFR2, blocking VEGF signaling (22).  Second, Serpin F1 binding to EC activates membrane gamma ‑secretase, resulting in the proteolytic cleavage of both VEGFR1 and R2, which abrogates signaling and creates a soluble receptor for VEGF (22, 23, 24).

目次に戻る

お問い合わせ先

(テクニカルサポート 試薬担当)

reagent@funakoshi.co.jp

製品情報は掲載時点のものですが、価格表内の価格については随時最新のものに更新されます。お問い合わせいただくタイミングにより製品情報・価格などは変更されている場合があります。
表示価格に、消費税等は含まれていません。一部価格が予告なく変更される場合がありますので、あらかじめご了承下さい。